ELV

Rating neutralTentativeAI MemoPost-earnings T+1

Elevance Health

As of 2026-10-22/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-22 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Delivery against raised 2026 earnings and cash-flow floors • 2027-02-15

Base target: $460 / p=50% prob

Biggest risk

The $1.85-per-share non-operating benefit clouds the quality of the EPS beat. Health Benefits operating gain fell year over year, adjusted operating expenses rose, and Medicare Advantage, Medicaid and Employer Group risk membership declined. The post-release closing decline argues against assuming an immediate re-rating [#SEC-8K-2026-10-21].

Invalidation

Break below $370 or thesis failure.

What would change my mind?

The Q3 adjusted EPS and revenue beat, 70-basis-point benefit-expense-ratio improvement, and increase in FY2026 adjusted EPS guidance to at least $29 support a more constructive view than the prior neutral baseline. Carelon growth and the reiterated 2027 growth objective provide a path to further upside, conditional on recurring operating gains [#SEC-8K-2026-10-21].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-22

Base target

$460

p=50%

Bull target

$500

p=30%

Bear target

$370

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-print reassessment of a qualified Q3 beat
Validate the 2027 adjusted EPS growth objective
The Q3 adjusted EPS and revenue beat, 70-basis-point benefit-expense-ratio improvement, and increase in FY2026 adjusted EPS guidance to at least $29 support a more constructive view than the prior neutral baseline.

BearKey bullets

A $1.85-per-share net non-operating benefit makes reported adjusted EPS less representative of recurring operating earnings [#SEC-8K-2026-10-21].
Adjusted operating expense ratio rose 90 basis points year over year, partly reflecting targeted investments [#SEC-8K-2026-10-21].
CarelonRx delegates certain core pharmacy services to CaremarkPCS under an agreement extending through December 31, 2027; the June 2026 filing does not quantify exposure, so this is an execution dependency rather than a measured earnings risk [#REL-7dd2c80b-84d1-4f93-b13b-7b9854b2b98f] (https://www.sec.gov/Archives/edgar/data/1156039/000115603926000060/elv-20260630.htm).

WatchKey bullets

Delivery against raised 2026 earnings and cash-flow floors

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $460 (p=50%)

Target spread vs base: +9% / -20%

Scenario probabilities

Bull Target: $500 (p=30%)Base Target: $460 (p=50%)Bear Target: $370 (p=20%)

Commentary

The primary-source beat and guidance raise improve the prior neutral thesis, consistent with the deterministic positive change signal, but the initial market response was mixed: ELV closed October 21 at $434.13, down about 1.37% from the October 20 close of $440.18 (price history). Pre-print consensus was $4.66 EPS and $48.60 billion revenue (Zacks preview); verified post-print analyst target or estimate revisions are unavailable. Social, options and employee measures are not covered by the packet, so the sentiment figures other than headline buzz should not be treated as measured signals.

As of 2026-10-22 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-print reassessment of a qualified Q3 beat
Validate the 2027 adjusted EPS growth objective

Scenarios

Bull Target (Scenario probability)

$500 / p=30% prob

Base Target (Scenario probability)

$460 / p=50% prob

Bear Target (Scenario probability)

$370 / p=20% prob

Analysis 2026-10-22 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-02-15
Delivery against raised 2026 earnings and cash-flow floors
Elevance raised its FY2026 adjusted EPS floor from at least $27.00 after Q2 to at least $29.00 after Q3, and raised operating cash-flow guidance to at least $6.5 billion. Year-end delivery will test whether improved claims performance offsets membership declines and higher operating expenses; the date is an estimated monitoring window, not an announced earnings date [#SEC-8K-2026-07-15] [#SEC-8K-2026-10-21].
Prob 65.00% • Move 5.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Post-print reassessment of a qualified Q3 beat
2026-11-15
Q3 adjusted EPS of $6.99 exceeded the $4.66 pre-print Zacks consensus, and operating revenue of $50.4 billion exceeded its $48.60 billion estimate. The company attributes part of EPS to a $1.85-per-share net non-operating benefit, while its benefit expense ratio improved 70 basis points to 90.6%. Whether investors credit the operating improvement rather than the non-operating gain is the immediate question [#SEC-8K-2026-10-21].
Prob 60% • Move 3% • Priced-in 65%

Long-term Catalysts

Months to a year

Validate the 2027 adjusted EPS growth objective
2027-12-31
Management reiterated confidence in at least 12% adjusted EPS growth in 2027 from a 2026 baseline of at least $26.75 that excludes specified non-recurring items and targeted one-time investments. Durable medical-cost control and Carelon gains must translate into recurring earnings for that objective to support a higher valuation; the date is a monitoring horizon [#SEC-8K-2026-10-21].
Prob 55% • Move 8% • Priced-in 50%

Risks

A $1.85-per-share net non-operating benefit makes reported adjusted EPS less representative of recurring operating earnings [#SEC-8K-2026-10-21].
Adjusted operating expense ratio rose 90 basis points year over year, partly reflecting targeted investments [#SEC-8K-2026-10-21].
CarelonRx delegates certain core pharmacy services to CaremarkPCS under an agreement extending through December 31, 2027; the June 2026 filing does not quantify exposure, so this is an execution dependency rather than a measured earnings risk [#REL-7dd2c80b-84d1-4f93-b13b-7b9854b2b98f] (https://www.sec.gov/Archives/edgar/data/1156039/000115603926000060/elv-20260630.htm).
Medicare Advantage, Medicaid and Employer Group risk membership fell; Health Benefits operating gain declined despite better medical-cost performance [#SEC-8K-2026-10-21].

Peers

Symbol	Summary
CI	Cigna is the closest direct managed-care and health-services comparator in the supplied peer set. Compare medical-cost discipline and services margins, while recognizing ELV-specific Medicaid and Carelon mix.
CVS	CVS offers a payer, pharmacy-benefit and services comparison. Its CaremarkPCS subsidiary is also a disclosed provider of certain core CarelonRx pharmacy services, so it is not an entirely independent read-through.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-22

Loading AI feed…

Symbol

Summary

Cigna is the closest direct managed-care and health-services comparator in the supplied peer set. Compare medical-cost discipline and services margins, while recognizing ELV-specific Medicaid and Carelon mix.

CVS

CVS offers a payer, pharmacy-benefit and services comparison. Its CaremarkPCS subsidiary is also a disclosed provider of certain core CarelonRx pharmacy services, so it is not an entirely independent read-through.